Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Fresenius Medical Care AG (FMS) over the last 16 years, with FY2024 value amounting to $1.3 billion.

  • Fresenius Medical Care AG's Cash & Equivalents fell 360.17% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 360.17%. This contributed to the annual value of $1.3 billion for FY2024, which is 1645.49% down from last year.
  • According to the latest figures from FY2024, Fresenius Medical Care AG's Cash & Equivalents is $1.3 billion, which was down 1645.49% from $1.5 billion recorded in FY2023.
  • Fresenius Medical Care AG's 5-year Cash & Equivalents high stood at $1.7 billion for FY2021, and its period low was $1.2 billion during FY2020.
  • Its 5-year average for Cash & Equivalents is $1.4 billion, with a median of $1.3 billion in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 3725.87% in 2021, then tumbled by 2079.42% in 2022.
  • Over the past 5 years, Fresenius Medical Care AG's Cash & Equivalents (Annual) stood at $1.2 billion in 2020, then surged by 37.26% to $1.7 billion in 2021, then fell by 20.79% to $1.3 billion in 2022, then grew by 14.38% to $1.5 billion in 2023, then dropped by 16.45% to $1.3 billion in 2024.
  • Its Cash & Equivalents was $1.3 billion in FY2024, compared to $1.5 billion in FY2023 and $1.3 billion in FY2022.